Cetera Investment Advisers Acquires 1,373 Shares of Smith & Nephew SNATS, Inc. $SNN

Cetera Investment Advisers boosted its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 8.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,748 shares of the medical equipment provider’s stock after acquiring an additional 1,373 shares during the quarter. Cetera Investment Advisers’ holdings in Smith & Nephew SNATS were worth $475,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Hexagon Capital Partners LLC lifted its position in Smith & Nephew SNATS by 63.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 406 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 1,701 shares in the last quarter. Hara Capital LLC lifted its position in shares of Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in shares of Smith & Nephew SNATS during the 1st quarter worth approximately $73,000. Finally, GAMMA Investing LLC lifted its position in shares of Smith & Nephew SNATS by 22.4% during the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider’s stock worth $103,000 after buying an additional 666 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 1.1%

NYSE:SNN opened at $36.20 on Monday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $15.85 billion, a PE ratio of 16.76, a price-to-earnings-growth ratio of 1.00 and a beta of 0.68. The firm’s 50 day moving average is $31.24 and its 200 day moving average is $28.87. Smith & Nephew SNATS, Inc. has a 12 month low of $23.69 and a 12 month high of $36.84.

Smith & Nephew SNATS Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be issued a $0.285 dividend. This represents a dividend yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s payout ratio is 41.20%.

Wall Street Analysts Forecast Growth

Several research firms have commented on SNN. Canaccord Genuity Group lifted their target price on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a “hold” rating in a research report on Thursday, May 1st. Hsbc Global Res cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Finally, HSBC cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.